C104450

Manufactured by Merck Group

The C104450 is a laboratory equipment product manufactured by Merck Group. It is designed for use in various scientific applications. The core function of this product is to provide a reliable and precise measurement tool for researchers and technicians in laboratory settings.

Automatically generated - may contain errors

Lab products found in correlation

Tubastatin a, by Merck Group (1 mentions) Bms 303141, by Merck Group (1 mentions) M7449, by Merck Group (1 mentions) Sml0784, by Merck Group (1 mentions) Sml0044, by Merck Group (1 mentions) Mg132, by Merck Group (1 mentions)

4 protocols using c104450

Quantifying PD-L1 Protein Dynamics

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells transfected with THADA siRNAs were co-incubated with cycloheximide (C104450, Sigma) (50 µg/mL) at the indicated time points, and subjected to western blot analysis. The intensity of each band was quantified by measuring gray values with the same-sized frame after subtracting background using ImageJ software (V.2.0.0-rc-69/1.52p). The relative PD-L1 intensity of each lane was normalized by the corresponding GAPDH intensity and the intensity at time point ‘0’.

Li C., Chi H., Deng S., Xu K., Wang H., Yao H., Wang Y., Chen D., Guo X., Fang J.Y., He F, & Xu J. (2021). THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. Journal for Immunotherapy of Cancer, 9(8), e002443.

+ Open protocol

+ Expand

Cycloheximide-Induced Protein Degradation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

HIP1R WT or HIP1R S929A transfected PDAC cells were incubated with 300 μg/mL cycloheximide (C104450, Sigma) under existing culture conditions. Cells were harvested at the indicated time points with RIPA buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate (SDS), 0.25% Na-deoxycholate) and a proteinase and phosphatase inhibitors (5 mM NaF and 0.2 mM sodium orthovanadate (NA₃VO₄), 2 μg/ml Aprotinin, 2 μg/ml Leupeptin, 2 μg/ml Pepstatin A, 1 mM DTT (dithiothreitol), 0.5 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), and 20 μM Chymotrypsin). The supernatant was collected and subjected to western blot analysis using antibody for HIP1R.

Koikawa K., Kibe S., Suizu F., Sekino N., Kim N., Manz T.D., Pinch B.J., Akshinthala D., Verma A., Gaglia G., Nezu Y., Ke S., Qiu C., Ohuchida K., Oda Y., Lee T.H., Wegiel B., Clohessy J.G., Sanatagata S., Wulf G.M., Hidalgo M., Muthuswamy S., Nakamura M., Gray N.S., Zhou X.Z, & Lu K.P. (2021). Targeting Pin1 Renders Pancreatic Cancer Eradicable by Synergizing with Immunochemotherapy. Cell, 184(18), 4753-4771.e27.

+ Open protocol

+ Expand

Investigating Tau Ubiquitination and HDAC Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

BMS 303141 (BMS), Tubastatin A (TubA), MG-132 and cycloheximide were obtained from Sigma-Aldrich (SML0784, SML0044, M7449, and C104450, respectively). MG-132 (20 µM) was added to fully differentiated cells 4 h prior to protein extraction. For ubiquitinated Tau MG-132 (17.5 µM) was added to HEK293 transfected cells 15 h prior to immunoprecipitation. Treatment of TubA, (2 µM) for 24 h alone or together with MG-132 (20 µM) for the last 4 h were added to fully differentiated cells, prior to protein extraction. BMS (1 µM) was added to fully differentiated cells for 72 h prior to cells fixation and immunofluorescence analysis.

Shilian M., Even A., Gast H., Nguyen L, & Weil M. (2022). Elongator promotes neuritogenesis via regulation of tau stability through acly activity. Frontiers in Cell and Developmental Biology, 10, 1015125.

+ Open protocol

+ Expand

Amlodipine Stability Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

After pre-treatment of amlodipine with or without the indicated small molecular inhibitors, cells were incubated with cycloheximide (C104450, Sigma) (50μg/mL) at the indicated time points, and detected by western blot assay. The bands were quantified by ImageJ (version 2.0.0-rc-69/1.52p). Each band was selected by the same-sized rectangular frame and the intensity of (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
the bands were measured after the subtraction of background. The intensity of each lane of PD-L1 was divided by the corresponding intensity of GAPDH for normalization. Ultimately, divided by the intensity at time point "0", the relative intensity was acquired to present the trend.

Li C., Yao H., Wang H., Fang J.Y, & Xu J. (2021). Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity. Oncogene, 40(6).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!